Our work demonstrates that the ALOX5‐5‐HETE axis promotes gastric cancer growth and alleviates chemotherapy toxicity via MEK/ERK activation and provides pre‐clinical evidence to initialize clinical trials using zileuton in combination with chemotherapy for the treatment of gastric cancer. Here, ALOX5 is linked to gastric cancer.